Antithrombotic drugs in secondary stroke prevention among a community dwelling older population
Why the study?
What percentage of older community-dwelling stroke survivors receive antithrombotic drugs for secondary prevention, and what factors are associated with their use?
Population
648 community-dwelling older individuals with a diagnosis of stroke, selected from 5,372 patients admitted…
Comparison
Antiplatelet or anticoagulant drugs vs No antiplatelet or anticoagulant drugs
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Highlights potential underuse of secondary prevention in community stroke survivors; leaves open whether addressing social/functional barriers improves antithrombotic uptake.
Structured PICO
What percentage of older community-dwelling stroke survivors receive antithrombotic drugs for secondary prevention, and what factors are associated with their use?
P
Population
648 community-dwelling older individuals with a diagnosis of stroke, selected from 5,372 patients admitted to home care programmes in Italy.
I
Intervention
Antiplatelet or anticoagulant drugs (most commonly aspirin and ticlopidine)
C
Comparator
No antiplatelet or anticoagulant drugs
O
Outcome
Percentage of stroke survivors receiving antiplatelet or anticoagulant drugs and factors associated with such treatment
A large majority (70%) of older, community-dwelling stroke survivors in home care do not receive antithrombotic therapy for secondary prevention, with underuse associated with social and functional impairments.
Cite This Study
Francesco Landi (2003) studied this question.